Northwestern University

Mar
20
Mon 4:00 PM

“Modulating Immune Response for the Treatment of B Cell Malignancies"

When: Monday, March 20, 2017
4:00 PM - 5:00 PM  

Where: Ward Building, 5-230, 303 E. Chicago Avenue, Chicago, IL 60611 map it

Audience: Faculty/Staff - Student - Public - Post Docs/Docs - Graduate Students

Contact: Alexa Nash   312.503.4893

Group: Department of Pharmacology Seminars

Category: Lectures & Meetings

Description:

The Department of Pharmacology is pleased to welcome Dr. Leon Huang, Ph.D., Senior Scientist, Abbvie Oncology Discovery.

The following, is an overview of this seminar, as described by Dr. Huang:

The idiotypic determinant (Id) of the immunoglobulin expressed by a B-cell malignancy can serve as a tumor antigen but is weakly immunogenic. We demonstrated that fusing CTLA-4 to Id represents an effective approach to prime antitumor immunities against B cell lymphoma and may be applicable to the treatment of other human cancers. IFN-alpha has potent immunostimulatory and antiproliferative effects against B-cell malignancies but its clinical utility is limited by systemic toxicity. We constructed a novel fusion protein consisting of anti-CD20 and IFN-alpha (IGN002) and demonstrated that IGN002 exhibited selective targeting and superior anti-tumor efficacy than rituximab. The results support the development of IGN002 for B-cell NHL treatment and first-in-human clinical studies are ongoing in the United States.

Add Event to Calendar

Add Event To My Group:

Please sign-in